The UK and US have agreed to a landmark bilateral deal that will preserve zero tariffs on UK medicine shipments entering the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to increase funding on pharmaceuticals through the public health system. This commitment guarantees that import taxes on these vital products will remain at nothing for a period of three years.
This agreement is in response to earlier warnings to hike tariffs on branded drug imports, with potential rates discussed reaching 100%.
"This arrangement between the Britain reinforces the international landscape for cutting-edge drugs and introduces much-needed balance to American-British drug exports," a statement noted.
Economic Importance
Drugs constitute one of the the United Kingdom's most significant export categories to the United States, which is by far the primary market for major companies like GSK and AstraZeneca.
Statistics indicate that in the year to the end of last September, the UK exported medicines worth £11.1bn to the US. This amount represented 17.4% of total UK exports in that period.
"This guarantee safeguards employment, boosts funding and facilitates the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The agreement entails several key changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new medicines to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to increase total public funding on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments exceeded twenty percent.
Broader Context
The pact comes amid a protracted dispute between the sector and the UK government over spending levels and NHS adoption.
These tensions were heightened by assertions that US patients were paying significantly more for the same drugs than people in the UK and Europe.
Recently, several large drug company projects in the UK have been paused or abandoned, while major investments have been pledged toward American operations.
A senior figure publicly accepted that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a share of its resources over the past decade.
